Of fish, flies, worms and men: Powerful approaches to neuropsychiatric disease using genetic models
Neuropsychiatric diseases are common; current therapies are only partially effective in controlling symptoms and there are no curative treatments. These diseases cause significant suffering and cost a staggering amount to society in treatment, care and lost productivity, and are consequently a high priority for research. The past two decades have witnessed an extraordinary expansion in our knowledge of the molecular basis of neurological diseases. Much of this progress has arisen through mapping gene loci in families with geneticallydetermined neurological diseases. The subsequent positional cloning of genes whose mutation provokes neurological disease has provided researchers with a solid foundation for investigating molecular mechanisms that might provide novel therapeutic targets. Although in some instances the relationship between common sporadic neurological diseases and their rare Mendelian phenocopies remains uncertain, the unequivocally causative connection between genetic mutation and disease etiology in hereditary diseases is important. There are few examples of sporadic neurological diseases in which the etiological factors are known in any detail, but it is expected that mechanistic commonality between genetic and sporadic forms of diseases will allow meaningful insights to be gained into the latter from understanding the former. This prediction is supported by the many clinical, pathologic and biochemical features that are shared between sporadic and hereditary forms of many diseases.
Advances in neurogenetics have provided some practical problems regarding the most effective way in which to exploit new information in order to move forward rapidly to detailed mechanistic understanding and new therapies. Although basic cell biological functions of proteins can be characterized rapidly in cultured cell lines, there are concerns that the mechanisms identified by these approaches might not be directly relevant to the abnormal functions of the proteins in disease. This is especially true in instances where mutation of a ubiquitously expressed gene provokes a specific neurological phenotype, suggesting that the pathogenically-relevant functions of the protein might be unique to a subpopulation of neural cells. Cultured neurons only partially address this question, since it is difficult to culture specific neuronal subpopulations of relevance in many instances, and it is becoming apparent that glial cells, the blood brain barrier, and the CNS internal environment may also play critical roles in pathogenesis of neurological disease (Boillee et al., 2006; Kordower et al., 2008; Li et al., 2008; Yamanaka et al., 2008) . In addition, functional disturbances underlying psychiatric disease and some movement disorders (for example dystonia) are not accompanied by cell death or known biochemical markers of cell dysfunction (Bressman and Ozelius, 2007) . In these circumstances, characterization of gene function might only be adequately accomplished in the context of neural circuits. Finally, many of the diseases show chronic evolution over a time course that could not be practicably mimicked in cultured cells. These considerations have led to the use of in vivo models of disease. Genetically-modified mice are now generated routinely; transgenic and gene knockout lines that recapitulate genetic abnormalities underlying human disease have provided key insights into pathogenesis through hypothesis-driven studies. However, the generation and maintenance of transgenic mouse colonies is laborintensive and there are practical limits on the number of experiments that can be carried out and consequently on the range of hypotheses that can be tested. This proves limiting in some situations; for example, when there are many alternative hypotheses or a number of putative modifier genes or environmental influences that might be important, an unmanageable number of experimental possibilities arises. The situation becomes more difficult when unsuspected mechanisms are important, since these might be overlooked by the traditional hypothesis-driven approaches than can be practicably deployed in murine models. These considerations have led some researchers to look to other experimental systems that might provide opportunities for higher-throughput in vivo approaches based on modification of phenotypic outcomes and unbiased by presumptions about mechanism. Three non-mammalian models that were well-established in other fields of biological research, Caenorhabditis elegans, Drosophila melanogaster and Danio rerio, have been adopted for studies of pathogenic mechanisms for this reason. Each of these model systems is represented in an emerging literature in neuropsychiatric disease research, in which the functional consequences of genetic manipulations that mimic human disease have been studied, the functions of relevant proteins elucidated in vivo, and in some cases unbiased phenotype-modifier screens carried out to reveal new pathogenic mechanisms. In this special issue of Neurobiology of Disease, we showcase some recent contributions of these model systems to our understanding of the molecular basis of neurological disease.
Worm. The nematode C. elegans was first employed for genetic studies in the early 1970s by Brenner, who shared the 2002 Nobel Prize for discoveries in programmed cell death made using this model system (Brenner, 1974; Sulston and Brenner, 1974) . The nervous system of this simple invertebrate organism is characterized by a highly uniform number of neurons that are stereotyped in terms of topology, neurochemistry and connectivity. Consequently, individual cells can be reliably identified experimentally; furthermore simple and reproducible motor behaviors can be used as assay end points. There is surprising phylogenetic conservation of genes implicated in human diseases and their homologues in C. elegans, allowing functional evaluation of many biochemical pathways of interest in vivo. Genetic techniques allow the expression of transgenes in specific neuronal populations, genes can be targeted using bacterial substrate expressing RNAi, and stable mutants can be recovered relatively easily from mutagenesis screens. C. elegans has a short generation time and 
